Page last updated: 2024-12-11

rifamycin b

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID5459948
CHEBI ID17876
SCHEMBL ID437936
MeSH IDM0105056

Synonyms (26)

Synonym
CHEBI:17876
4-o-(carboxymethyl)rifamycin
acetic acid, ((1,2-dihydro-5,6,17,19,21-pentahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-1,11-dioxo-2,7-(epoxypentadeca(1,11,13)trienimino)naphtho(2,1-b)furan-9-yl)-oxy)-, 21-acetate
[(2s,12z,14e,16s,17s,18r,19r,20r,21s,22r,23s,24e)-21-acetyloxy-5,6,17,19-tetrahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-1,11-dioxo-1,2-dihydro-2,7-(epoxypentadeca[1,11,13]trienoimino)naphtho[2,1-b]furan-9-yloxy]acetic acid
nsc 145604
einecs 237-697-8
C01848
rifamycin b
2-(acetoxy-tetrahydroxy-methoxy-heptamethyl-dioxo-[?]yl)oxyacetic acid
nancimycin
LMPK05000003
8ddb535dji ,
unii-8ddb535dji
SCHEMBL437936
rifamycin sodium impurity a [ep impurity]
((2s,12z,14e,16s,17s,18r,19r,20r,21s,22r,23s,24e)-21-(acetyloxy)-5,6,17,19-tetrahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-1,11-dioxo-1,2-dihydro-2,7-(epoxypentadeca(1,11,13)trienazano)naphtho(2,1-b)furan-9-yl)acetic acid
rifamycin b [mi]
rifaximin impurity b [ep impurity]
AKOS030489430
J-007262
Q27102689
o[2,1-b]furan-9-yl]oxy}acetic acid
{[(2s,12z,14e,16s,17s,18r,19r,20r,21s,22r,23s,24e)-21-(acetyloxy)-5,6,17,19-tetrahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-1,11-dioxo-1,2-dihydro-2,7-(epoxypentadeca[1,11,13]trienoimino)naphth
STL564327
2-[[(7s,9e,11s,12r,13s,14r,15r,16r,17s,18s,19e,21z)-13-acetyloxy-2,15,17,29-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-27-yl]oxy]acetic acid
DTXSID901037384

Research Excerpts

Overview

Rifamycin B is an important polyketide antibiotic used in the treatment of tuberculosis and leprosy.

ExcerptReferenceRelevance
"Rifamycin B is an important polyketide antibiotic used in the treatment of tuberculosis and leprosy. "( Optimization of rifamycin B fermentation in shake flasks via a machine-learning-based approach.
Bapat, PM; Wangikar, PP, 2004
)
2.11
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (4)

ClassDescription
rifamycins
carboxylic acidA carbon oxoacid acid carrying at least one -C(=O)OH group and having the structure RC(=O)OH, where R is any any monovalent functional group. Carboxylic acids are the most common type of organic acid.
acetate esterAny carboxylic ester where the carboxylic acid component is acetic acid.
organic heterotetracyclic compound
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (65)

TimeframeStudies, This Drug (%)All Drugs %
pre-199020 (30.77)18.7374
1990's19 (29.23)18.2507
2000's17 (26.15)29.6817
2010's8 (12.31)24.3611
2020's1 (1.54)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 25.88

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index25.88 (24.57)
Research Supply Index4.29 (2.92)
Research Growth Index4.38 (4.65)
Search Engine Demand Index31.58 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (25.88)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (2.78%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other70 (97.22%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]